Maravai LifeSciences Holdings Inc Ordinary Shares - Class A MRVI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MRVI is a good fit for your portfolio.
News
-
TriLink BioTechnologies® Announces New San Diego Facility for Late Phase mRNA Drug Substance Production
-
Maravai LifeSciences To Host Earnings Conference Call on Wednesday, May 8, 2024
-
Maravai LifeSciences Announces March 2024 Investor Conference Schedule
-
Thinking about buying stock in Maravai Lifesciences, Abercrombie & Fitch, elf Beauty, IONQ, or Vanda Pharmaceuticals?
-
Maravai LifeSciences Reports Fourth Quarter and Full Year 2023 Financial Results
-
TriLink BioTechnologies® Solidifies IP Position with Awarded Patents for CleanCap® Capping Technology in China and Canada
-
Dyadic and Cygnus Technologies Announce Partnership To Provide C1 HCP ELISA Assay to Enhance Quality Assurance in Biomanufacturing
-
Maravai LifeSciences To Host Earnings Conference Call on Thursday, February 22, 2024
Trading Information
- Previous Close Price
- $7.58
- Day Range
- $7.50–7.82
- 52-Week Range
- $4.52–16.62
- Bid/Ask
- $7.70 / $7.71
- Market Cap
- $1.02 Bil
- Volume/Avg
- 1.3 Mil / 2.8 Mil
Key Statistics
- Price/Earnings (Normalized)
- 150.58
- Price/Sales
- 3.52
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, and novel vaccines and supports research on human diseases. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 650
- Website
- https://www.maravai.com
Comparables
Valuation
|
Metric
|
MRVI
|
TIHE
|
ADPT
|
|---|---|---|---|
Price/Earnings (Normalized) | 150.58 | — | — |
Price/Book Value | 2.44 | — | 1.23 |
Price/Sales | 3.52 | — | 2.21 |
Price/Cash Flow | 35.79 | — | — |
Price/Earnings
MRVI
TIHE
ADPT
Financial Strength
|
Metric
|
MRVI
|
TIHE
|
ADPT
|
|---|---|---|---|
Quick Ratio | 7.21 | — | 4.37 |
Current Ratio | 8.00 | — | 4.66 |
Interest Coverage | 13.86 | — | −16.45 |
Quick Ratio
MRVI
TIHE
ADPT
Profitability
|
Metric
|
MRVI
|
TIHE
|
ADPT
|
|---|---|---|---|
Return on Assets (Normalized) | −30.00% | — | −18.06% |
Return on Equity (Normalized) | −126.21% | — | −35.04% |
Return on Invested Capital (Normalized) | −41.97% | — | −28.06% |
Return on Assets
MRVI
TIHE
ADPT
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Tczsnszwb | Nyt | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Djqwvyrm | Mpddlzw | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Xgfcqvp | Vhdpthn | $97.8 Bil | |
MRNA
| Moderna Inc | Bfrxkdzb | Nxth | $41.3 Bil | |
ARGX
| argenx SE ADR | Wlmtpqjww | Fdpf | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Rcqcqvbwt | Vjxqz | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Nwzbzcsr | Gsmnw | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Xwpdvbygq | Kfbhhty | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ythbhrddf | Zsrcmk | $12.5 Bil | |
INCY
| Incyte Corp | Svfxctfq | Rbxsf | $11.6 Bil |